Alberati Daniela, Ceccarelli Simona M, Jolidon Synèse, Krafft Eva A, Kurt Anke, Maier Axel, Pinard Emmanuel, Stalder Henri, Studer Deborah, Thomas Andrew W, Zimmerli Daniel
Discovery Biology, F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Switzerland.
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4305-10. doi: 10.1016/j.bmcl.2006.05.064. Epub 2006 Jun 9.
A novel class of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-ones have been discovered and developed as potent and selective GlyT1 inhibitors. The molecules are devoid of activity at the GlyT2 isoform and display excellent selectivities against the mu opioid receptor as well as the nociceptin/orphanin FQ peptide (NOP) receptor. A novel, straightforward and efficient synthetic strategy for the assembly of the target molecules is also presented.